Erik Hertervig

Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study

Gunnar Järnerot, Erik Hertervig, Ingalill Friis–Liby et al. · Gastroenterology · 2005 · 1.1K citations · Full text

Inflammation, Anti-inflammatory, Gastroenterology +5

Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

Viktoria Bergqvist, Erik Hertervig, Peter Gedeon et al. · Cancer Immunology Immunotherapy · 2017 · 233 citations · Full text

Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

Ryan C. Ungaro, Clara Yzet, Peter Bossuyt et al. · Gastroenterology · 2020 · 227 citations · Full text

Inflammation, Chronic Inflammatory Diseases, Deep Remission +8

Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study

A. Gustavsson, G Järnerot, Erik Hertervig et al. · Alimentary Pharmacology & Therapeutics · 2010 · 179 citations · Full text

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Édouard Louis, Matthieu Resche‐Rigon, David Laharie et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 101 citations · Full text

Autoimmune Disease, Immunosuppressive Therapy, Immunology +7